Pancreatic Ductal Adenocarcinoma (PDAC) is the 10th most common type of pancreatic cancer. In the Czech Republic in 2022, more than 2,400 people were diagnosed with this cancer. Of these, approximately 2,100 patients, what is more than 87%, will succumb to the disease. Late diagnosis of pancreatic cancer is the main reason for this high death rate.
The new LIPIDICA test
It is difficult to diagnose pancreatic cancer because the disease has few obvious or typical symptoms, at least in the early stages. Currently, there is no preventive screening programme and the current diagnostic methods (EUS, MR/MRCP, CT scan) are expensive and unpleasant for the patient. The LDPC lipidomic test makes it possible to diagnose pancreatic cancer using a normal blood sample. This non-invasive test offers the opportunity to establish a screening program which could improve treatment outcomes and save lives.
About the LIPIDICA project
The main goal of Lipidica, a.s. is to develop and promote effective, laboratory-based, non-invasive and early diagnosis of malignant neoplasms worldwide. The project is based on fundamental research in the use of lipidome analysis, coupled with mathematical modelling and artificial intelligence algorithms. Lipidica is prepared for ongoing collaboration with the best clinical and research institutions in the practical application of diagnostic methods to help save lives.